Name: Cagrilintide
Brand: PeptidesDirect
SKU: PD-CAGRILINTIDE-10MG
Price: 79.99 EUR
Availability: OutOfStock
Rating: 5.00 (1 reviews)

Question 1

What is Cagrilintide?

Accepted Answer

Cagrilintide is a long-acting synthetic analog of the human hormone amylin, developed under the code AM833. It binds amylin receptors in the brainstem and slows gastric emptying, mechanisms independent of the GLP-1 pathway used by semaglutide or tirzepatide. Phase 3 REDEFINE trials are complete and the FDA decision is expected in late 2026.

Question 2

How should I store Cagrilintide?

Accepted Answer

Store lyophilized Cagrilintide at -20°C for long-term storage or at 2-8°C for short-term use. Once reconstituted, keep refrigerated at 2-8°C and use within 4 weeks. Protect from light at all times.

Question 3

What purity is your Cagrilintide?

Accepted Answer

Every batch of Cagrilintide ships with a certificate of analysis from Janoshik Analytical, an independent third-party laboratory, at a minimum purity of 98%. We do not run a lab ourselves: the manufacturer commissions this test, and we pass the report on unchanged, with an online verification link on the product page.

Question 4

How do I reconstitute Cagrilintide?

Accepted Answer

Cagrilintide is an amylin analog and dissolves poorly in plain bacteriostatic water. Dissolve the powder in a small amount of dilute acetic acid water first, then top it up to your target volume with bacteriostatic water. Add liquid slowly along the inside wall of the vial and swirl gently until dissolved, never shake. The vial we sell is 10 mg. Make sure the solution is clear before use.

Question 5

What has cagrilintide actually been studied for, and in what trials?

Accepted Answer

Cagrilintide has been studied for weight management in adults with overweight or obesity, and for weight loss plus glycemic control in adults with type 2 diabetes, always given by injection and almost always compared against or combined with semaglutide. A phase 2 monotherapy trial dosed it alone in non-diabetic adults (PMID 34798060), phase 1b and phase 2 trials paired it with semaglutide as CagriSema in adults with and without diabetes (PMID 33894838, PMID 37364590), and the phase 3 REDEFINE 1 and REDEFINE 2 trials tested CagriSema in obesity and in type 2 diabetes respectively (PMID 40544433, PMID 40544432). A separate mouse study examined the brain amylin receptors behind the effect (PMID 40609154). All of this remains investigational: no regulator has approved cagrilintide as a standalone medicine.

Question 6

What dose did the cagrilintide studies use (species, route, frequency, duration), and is there a published human dosing protocol?

Accepted Answer

In a mouse mechanism study, wild type mice received cagrilintide at 0.3, 3 or 30 nmol per kg per day, subcutaneous, once daily, for 21 days (PMID 40609154). That is what the study administered in mice, and it was not converted into a human dose. Human phase 3 trials such as REDEFINE 1 dosed adults with a fixed 2.4 mg of cagrilintide subcutaneously once weekly for 68 weeks, escalated gradually under close clinical supervision (PMID 40544433). That was a closely monitored, sponsor run clinical trial protocol, not a published dosing protocol for self administered or non clinical use, and no such protocol exists.

Question 7

What did the cagrilintide trials find, and how quickly did the effect show up?

Accepted Answer

In the phase 3 REDEFINE 1 trial, CagriSema (cagrilintide plus semaglutide) produced 20.4% mean weight loss at week 68 versus 3.0% on placebo, while cagrilintide alone in the same trial produced 11.5%, weaker than semaglutide alone at 14.9% (PMID 40544433). An earlier phase 1b trial already showed 15.4 to 17.1% weight loss with different CagriSema doses by week 20, versus 8.0 to 9.8% on placebo, so an effect is measurable well before the 68 week endpoint (PMID 33894838). In the mouse mechanism study, cagrilintide's appetite suppressing effect faded after about 3 days even though the weight change persisted over the full 21 day study (PMID 40609154).

Question 8

What side effects or adverse events were reported in the cagrilintide trials, with rates and citations?

Accepted Answer

Gastrointestinal events, nausea, vomiting, diarrhea and constipation, are the dominant adverse event across every published cagrilintide trial. In the phase 2 monotherapy trial, 41 to 63% of people on cagrilintide alone had a GI event versus 32% on placebo, with nausea in 20 to 47% versus 18% on placebo, and administration-site reactions in 13.0 to 42.6% of people (dose dependent) versus 13.1% on liraglutide and 3.0% on placebo (PMID 34798060). In REDEFINE 1, GI event rates were 54.0% on cagrilintide alone, 73.8% on semaglutide alone and 79.6% on the CagriSema combination, versus 39.9% on placebo (PMID 40544433). None of the administration-site reactions in the phase 2 trial were classed as severe, and few led to treatment discontinuation.

Question 9

What is not known about cagrilintide's long-term safety, i.e. what is the honest evidence gap?

Accepted Answer

The longest published cagrilintide trials run 68 weeks (REDEFINE 1 and REDEFINE 2), so there is no published human safety data beyond about 16 months of exposure (PMID 40544433, PMID 40544432). Every human cagrilintide trial to date was funded by Novo Nordisk, the drug's own developer, a real conflict of interest to weigh when reading the safety conclusions. There is no published trial in pregnancy, breastfeeding, adolescents or children, and the earliest safety and pharmacokinetics study exposed only 95 people, too few to detect rare adverse events (PMID 33894838). A search of the published literature found no case reports specific to cagrilintide outside these sponsor run trials, so the entire public safety picture currently comes from that same small set of studies.

Question 10

Is cagrilintide approved by the FDA, EMA, or any regulator, or is it strictly a research compound?

Accepted Answer

Cagrilintide itself has never been submitted for approval as a standalone drug. Novo Nordisk filed a US FDA New Drug Application on 18 December 2025, but only for CagriSema, the fixed combination of cagrilintide with semaglutide, not for cagrilintide alone, and the FDA's review is expected to run through 2026. No regulator, FDA, EMA or otherwise, has approved cagrilintide or CagriSema for any use as of this writing. It remains an investigational, research only compound.

Question 11

What does our own third-party CoA show for cagrilintide, and how can a specific batch be verified?

Accepted Answer

Our current batch (labelled Red) was tested by Janoshik at 99.68% purity with 11.45 mg measured content in a vial labelled 10 mg, dated November 2025. That test, like most of our lab reports, was commissioned by the manufacturer rather than by us as an independent purchase, and we publish the result unchanged. You can check this exact result against Janoshik's own record at verify.janoshik.com/tests/86685_J3EQW2TEZQKZ, the same link shown on the product page and our /coa lab reports page.

Question 12

How does cagrilintide compare to semaglutide and tirzepatide in mechanism and trial evidence?

Accepted Answer

Cagrilintide is an amylin-receptor agonist, while semaglutide and tirzepatide act on GLP-1 (and, for tirzepatide, also GIP) receptors, a different pathway; a mouse study traced cagrilintide's effect specifically to the AMY1R and AMY3R receptors in the brain (PMID 40609154). In head-to-head human data, cagrilintide alone is the weakest of the three: REDEFINE 1 measured 11.5% weight loss with cagrilintide alone versus 14.9% with semaglutide alone at week 68 (PMID 40544433). Cagrilintide's main published role is as the amylin half of CagriSema (cagrilintide plus semaglutide), where the combination outperformed either drug alone in that same trial at 20.4%. No published trial has reported cagrilintide-alone results head to head against tirzepatide.

Question 13

Is cagrilintide the same thing as CagriSema, or is that a different product?

Accepted Answer

No. Cagrilintide is a single molecule, a long acting amylin analog; CagriSema is Novo Nordisk's name for a fixed dose combination product containing both cagrilintide (2.4 mg) and semaglutide (2.4 mg) in one weekly injection. Most of the large trial results, REDEFINE 1, REDEFINE 2 and REDEFINE 4, tested CagriSema, the combination, so headline numbers like 20.4% or 23% weight loss belong to the two drug combination, not to cagrilintide by itself (PMID 40544433). What we sell is cagrilintide only, as a single peptide vial; it does not contain semaglutide.

Question 14

Does cagrilintide work better alone or combined with semaglutide, based on the trial data?

Accepted Answer

In the head-to-head REDEFINE 1 trial, cagrilintide alone produced 11.5% mean weight loss at week 68, semaglutide alone produced 14.9%, and the CagriSema combination produced 20.4%, all versus 3.0% on placebo (PMID 40544433). The combination outperformed either drug alone, and cagrilintide monotherapy was the weakest of the three active arms in that trial. The same pattern held in the smaller phase 1b and phase 2 diabetes trials, where the combination consistently beat cagrilintide alone on both weight loss and HbA1c (PMID 33894838, PMID 37364590).

Question 15

Did the cagrilintide trials measure any effect on blood glucose or HbA1c?

Accepted Answer

Yes, in the two trials that enrolled people with type 2 diabetes. In the phase 2 Frias trial, HbA1c fell by 0.9 percentage points on cagrilintide alone over 32 weeks, versus 1.8 points on semaglutide alone and 2.2 points on the CagriSema combination, with no level 2 or 3 hypoglycemia reported in any arm (PMID 37364590). In REDEFINE 2, 73.5% of people on the CagriSema combination reached an HbA1c of 6.5% or below at week 68, versus 15.9% on placebo, though that trial dosed the combination rather than cagrilintide alone (PMID 40544432).

Question 16

Did the cagrilintide trials report any effect on heart rate or blood pressure?

Accepted Answer

Yes, several trials measured this, and cagrilintide or CagriSema generally reduced blood pressure. In REDEFINE 1, CagriSema reduced systolic blood pressure by 9.9 mmHg and diastolic blood pressure by 5.0 mmHg at week 68, versus 3.2 and 1.9 mmHg with placebo, while heart rate barely moved (0.94 beats per minute with CagriSema, minus 3.31 with cagrilintide alone, 1.17 with semaglutide alone, minus 0.58 with placebo) (PMID 40544433). REDEFINE 2 found a similar systolic blood pressure reduction in people with type 2 diabetes, 6.5 mmHg versus 2.4 mmHg with placebo (PMID 40544432). The phase 2 monotherapy trial also reported reduced blood pressure across every cagrilintide dose, with small, dose dependent changes in pulse rate (PMID 34798060).

Question 17

Have any published cagrilintide trials tested a dosing frequency other than once weekly?

Accepted Answer

No. Every human cagrilintide trial found, from the earliest phase 1b study through REDEFINE 1, REDEFINE 2 and REDEFINE 4, dosed it once weekly by subcutaneous injection; none tested a twice weekly or split dose schedule (PMID 33894838, PMID 40544433, PMID 40544432). The one exception is the mouse mechanism study, which used once daily subcutaneous dosing in animals over 21 days, a different model and species entirely (PMID 40609154). No published human data exists for any dosing interval other than once weekly.

Question 18

What did the newest head-to-head trial (REDEFINE 4) find comparing CagriSema to tirzepatide?

Accepted Answer

Novo Nordisk announced topline results from REDEFINE 4 on 23 February 2026, an 84 week open-label phase 3 trial in 809 adults with obesity comparing CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) against tirzepatide 15 mg. Under the trial's efficacy estimand, CagriSema produced 23.0% mean weight loss versus 25.5% with tirzepatide, so the trial did not meet its primary endpoint of non-inferiority. This is press release topline data only, not yet a peer-reviewed publication, and like the other CagriSema results it describes the combination, not cagrilintide by itself.

Question 19

What is cagrilintide made of: molecular weight, amino acid count, fatty-acid modification, and CAS number?

Accepted Answer

Cagrilintide is a 37-amino-acid amylin analogue, built on the human amylin backbone, with a C20 fatty diacid attached through a gamma-Glu-AEEA linker. That fatty-acid tail promotes albumin binding in the bloodstream, the same long-acting design principle used in semaglutide, which is why cagrilintide needs only once-weekly dosing in the trials that have tested it. Its registered identifiers are CAS 1415456-99-3, molecular formula C194H312N54O59S2, and a molar mass of approximately 4409 g/mol, the same figures shown on this product's spec sheet. Batch-specific purity and measured content are confirmed separately on our third-party CoA, not by this chemical identity data.

Question 20

Did any cagrilintide trial specifically test cardiac rhythm (the QT interval), separate from general heart rate or blood pressure?

Accepted Answer

Yes. A dedicated thorough QT study in healthy participants, the type of trial regulators require to test a drug's effect on cardiac electrical recovery, dose-escalated cagrilintide to 4.5 mg once weekly, above the 2.4 mg used in the weight-management trials, and measured the QTcF interval at 12, 24, 48 and 72 hours after the final dose (PMID 39279639). It found no clinically relevant QTcF prolongation at any time point, with a positive control (moxifloxacin) confirming the study could detect a true signal if one existed. This is a separate, more specific endpoint than the heart-rate and blood-pressure changes already covered in our other FAQ answer.

Question 21

How is the mg-per-mL concentration of a cagrilintide vial worked out from vial strength and water volume?

Accepted Answer

For our single 10 mg vial, 1 to 2 mL of diluent gives roughly 5 to 10 mg per mL: the volume chosen sets the final concentration, not how long the peptide stays intact. Cagrilintide sits in our acidic pH-sensitivity tier, since amylin-class peptides are typically formulated closer to pH 4 in the published literature, so plain bacteriostatic water (USP pH 5.7) is not always the best match, and a dilute acetic-acid diluent is generally the better choice. What actually governs stability after reconstitution is temperature and time, not the exact ratio used.

Question 22

How should an unreconstituted cagrilintide vial be stored (fridge vs freezer), and how long does the reconstituted solution remain stable?

Accepted Answer

Unopened, lyophilized cagrilintide keeps longest stored frozen at around -20°C; refrigerated at 2-8°C is fine for shorter stretches. Either way, keep it dark and dry until you are ready to reconstitute. Once reconstituted, move it to the refrigerator rather than the freezer: refreezing a dissolved solution risks damaging the peptide. Reconstituted peptide solutions are generally treated as usable for around 28 days under refrigeration, in line with our other reconstitution-sensitive products, though this has not been formally shelf-life tested by us or the manufacturer. A solution that turns cloudy and stays cloudy should be discarded rather than used past that window.

Question 23

Does cagrilintide-driven weight loss come from fat mass, or does it also reduce lean muscle mass, based on the published research?

Accepted Answer

The clearest data on this comes from a mouse mechanism study, not a human trial: over a 21-day course, cagrilintide-treated mice lost about 7% of fat mass while lean mass rose about 5%, though neither change reached statistical significance (PMID 40609154). Taken at face value that hints at a fat-favoring shift rather than simple muscle wasting, at least in this animal model, but the numbers are too small to be conclusive. The human phase 3 trials (REDEFINE 1, REDEFINE 2) reported total body weight change only, not a fat-versus-lean breakdown, so how that mouse finding translates to people over months of treatment remains an open question.

Question 24

Has cagrilintide been studied or is it commonly stacked with retatrutide, not just semaglutide?

Accepted Answer

No published clinical trial has tested cagrilintide together with retatrutide. Cagrilintide and semaglutide are both Novo Nordisk molecules studied together as CagriSema across several phase 1 to 3 trials, but retatrutide is an unrelated triple agonist from a different originator (Eli Lilly), with no joint development program and no combined trial data of any kind. Any cagrilintide-plus-retatrutide use discussed in research-market circles is informal practice pieced together from separate single-agent studies, not evidence from a trial that tested the two together, and we do not offer or endorse a combined protocol.

Question 25

Is cagrilintide linked to the mood/suicidal-ideation and hair-loss concerns now under FDA review for GLP-1-class drugs?

Accepted Answer

No published cagrilintide trial has reported on mood, depression, or suicidal ideation as an outcome, and we are not aware of any cagrilintide-specific data addressing the current FDA review. Mechanistically, cagrilintide is an amylin-receptor agonist, distinct from the GLP-1-class drugs (semaglutide, liraglutide, tirzepatide) that the review concerns, but whether that difference matters for these particular safety signals has not been studied and should not be assumed either way. Hair loss has not been reported as a specific adverse event in the published cagrilintide trials, whose recorded side effects are mainly gastrointestinal and injection-site reactions. This remains an open regulatory question, not a settled one.

Question 26

Is it legal to buy cagrilintide as a research compound in the EU?

Accepted Answer

We sell cagrilintide strictly as a laboratory research chemical, not as a medicine, supplement, or product intended for human or animal use, and it carries no FDA, EMA, or other regulatory marketing authorization as a standalone compound. That research-use-only positioning is the basis on which we ship it across the EU. We are not able to give country-by-country legal or customs advice: import rules, personal-use allowances, and enforcement practice vary by member state and can change, so a buyer intending to bring cagrilintide into a specific jurisdiction should check that country's own current regulations before ordering.

Question 27

Does unrefrigerated shipping affect the quality of this product?

Accepted Answer

No. This product ships as a lyophilized (freeze-dried) powder in a sealed vial. Freeze-drying removes the water that drives peptide degradation, so the dry powder remains stable at room temperature for extended periods, longer than any normal parcel transit. Ambient shipping is standard practice across the peptide industry, and a peer-reviewed study reported months of room-temperature stability for a lyophilized therapeutic peptide (teriparatide, PMID 26620825). For comparison, FDA labeling allows an Ozempic (semaglutide) pen, after first use, to be kept out of the fridge for 56 days at 15 to 30°C, and a Mounjaro (tirzepatide) pen for up to 21 days at up to 30°C, even though these are ready-mixed solutions rather than sealed dry powder. Store the sealed vial in the fridge or freezer for long-term storage, and always refrigerate after reconstitution.

Question 28

What is eloralintide, and how does its published data compare to cagrilintide's?

Accepted Answer

Eloralintide (Eli Lilly's LY3841136) is an investigational once-weekly selective amylin-receptor agonist, a different molecule from Novo Nordisk's cagrilintide, engineered for selectivity toward the amylin-1 receptor (about 12-fold over the calcitonin receptor in vitro, PMID 41109426). Its published human record: a phase 1 single-ascending-dose study (48 healthy participants), a 12-week phase 1 proof-of-concept (100 participants), and the 48-week phase 2 in 263 adults with obesity, where mean weight change reached about minus 20 percent in the highest dose arms versus placebo (PMID 41207310), with nausea ranging from 11 to 64 percent across active arms (not monotonic by dose) versus 14 percent on placebo, plus fatigue. Cagrilintide's comparable published anchor is phase 3: monotherapy produced 11.5 percent mean weight loss at week 68 in REDEFINE 1 (PMID 40544433), where the cagrilintide-semaglutide combination did more. Three cautions before reading that as a ranking: there is no head-to-head trial, so any eloralintide-versus-cagrilintide comparison is cross-trial with different durations, populations and phases; all eloralintide trials are sponsor-funded and US-based; and the rat finding that eloralintide caused less taste avoidance than cagrilintide is a preclinical nausea proxy, not a human tolerability result. Eloralintide has no EU marketing authorisation and remains investigational, now in phase 3, so its dataset is several years behind cagrilintide's.

Question 29

Why do people add cagrilintide to a Retatrutide or tirzepatide stack, what's the receptor logic, and has that pairing been studied?

Accepted Answer

The receptor logic is real; the pairing data are not. Cagrilintide works through amylin receptors, which are calcitonin-receptor complexes (AMY1R/AMY3R, PMID 40609154), a completely different system from retatrutide's GLP-1, GIP and glucagon receptors (PMID 37366315), so the appeal is stacking a fourth, non-overlapping satiety pathway on top of three. The only human evidence that an amylin agonist adds to an incretin drug is CagriSema, cagrilintide plus SEMAGLUTIDE, whose phase 3 programme (REDEFINE 1, over 3,400 participants, PMID 40544433) showed the combination outperforming either component alone. Two honest limits on transferring that: semaglutide is a single-receptor GLP-1 drug, so 'amylin adds on top' is demonstrated for a much narrower base than retatrutide's triple agonism, where the incremental headroom is unknown; and no human study was identified combining cagrilintide with retatrutide or tirzepatide; the only pairing evidence of any kind is a 2024 rat study reported as a conference abstract (with tirzepatide), preclinical and unreviewed, and the popular 'add it when appetite suppression fades' timing has no study behind it in any species. Worth adding from the trial record: retatrutide's own phase 2 curve was still descending at 48 weeks at the top dose (minus 24.2 percent and falling, PMID 37366315), so the plateau that motivates the add-on often is not what the drug showed on-trial. Combination safety for this specific pairing: no study identified in any species.

Question 30

How common is fatigue or tiredness on cagrilintide, and how severe is it in the published trials?

Accepted Answer

The numbers exist and are worth having precisely, because the abstracts hide them. Cagrilintide alone: in the phase 2 dose-finding trial, fatigue ran from 5.0 to 19.8 percent across dose arms, highest at the top 4.5 mg dose, though not rising smoothly with dose in between (structured trial results for NCT03856047, PMID 34798060); no fatigue term appears among that trial's reported serious adverse events, which describes those tables rather than establishing a severity ceiling. In REDEFINE 1 (PMID 40544433, supplementary tables): fatigue in 14.2 percent on cagrilintide alone, 13.6 percent on semaglutide alone, 20.8 percent on the CagriSema combination, versus 6.4 percent on placebo, with asthenia (weakness) similarly elevated on the combination; the near-identical monotherapy rates suggest the tiredness is not unique to the amylin mechanism, though no identified study isolates whether drug pharmacology or the induced caloric deficit produces it. The 2026 BMJ network meta-analysis puts CagriSema's fatigue risk ratio around 3.2 versus placebo, among the higher values in the obesity-drug field (PMID 42419792). What no identified study isolates: mechanism, whether the fatigue is drug pharmacology or simply the caloric deficit it creates, and no identified trial publication reports fatigue-specific discontinuation. So: common, dose-tilted, more frequent when combined with a GLP-1 drug, absent from the reported serious-adverse-event tables, and mechanistically unattributed.

Cagrilintide

What is Cagrilintide

How it works

Often studied alongside

Documentation

Storage and stability

Reviews

Frequently Asked Questions

Technical data sheet

Frequently bought together

Retatrutide

AOD-9604

Tesamorelin

Acetic Acid Water

Bacteriostatic Water

Lab Measuring Syringe + Prep Wipes Set (1 mL 31G)

Graduated Measuring Syringe 1 mL 31G x 6 mm

Alcohol Prep Pads 30 x 65 mm

Peptide Storage Box (10 Compartments)

Peptide Vial Case 30 Slots